【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com (责任编辑：宋政 HN002) 格隆汇8月6日｜隔夜美股三大指数集体收跌，中概指数跌0.56%。连续2日反弹的港股三大指数低开， 恒指跌0.15%，国指跌0.21%，恒生科技指数跌0.31%。盘面上，大型科技股多数呈现下跌行情，其中， 百度跌超1%，阿里巴巴、小米、美团、网易均飘绿，腾讯、京东小幅上涨；创新药概念股继续走强， 与DoveTree完成总订单规模约470亿港元的管线合作签约，晶泰科技大涨15%，歌礼制药、康方生物、 远大医药、金斯瑞生物科技皆上涨；宇树发布新款四足机器狗，机器人概念股多数活跃，纸业股继续昨 日上涨。另一方面，餐饮股走低，百胜中国跌超6%，钢铁股、汽车股、电信股、快递物流股普遍下 跌。(格隆汇) ...

Core Insights - The MASH market is experiencing significant growth, with Madrigal's drug Rezdiffra achieving sales of $317 million in its first year, including $137 million in Q1 of this year [1][3][5] - The competitive landscape is intensifying, with multiple companies developing drugs targeting various mechanisms, including THRβ, GLP-1, and FGF21 [1][2][11] - Madrigal has entered a collaboration with CSPC to acquire global rights to the oral GLP-1 agonist SYH2086, aiming to combine it with Rezdiffra for enhanced treatment [1][8] Group 1: Market Performance - Rezdiffra has shown strong sales performance, exceeding market expectations, with quarterly sales increasing significantly since its launch [3][5] - The drug has demonstrated clear clinical benefits in a Phase 3 study, with 25.9% and 29.9% of patients achieving MASH resolution without worsening fibrosis [6] - The patient penetration rate for Rezdiffra remains low at 5%, indicating substantial growth potential in the target population [6][7] Group 2: Competitive Landscape - The MASH treatment landscape is evolving from single-target competition to multi-target strategies, with a focus on combination therapies [2][11] - GSK's acquisition of FGF21 agonist Efimosfermin alfa for $2 billion highlights the increasing interest in this therapeutic area [1][11] - Companies like Akero are also making strides with their FGF21-based therapies, showing promising results in reversing liver fibrosis [11][12] Group 3: Strategic Collaborations - Madrigal's partnership with CSPC to develop a dual oral therapy combining Rezdiffra and SYH2086 reflects a strategic move to enhance treatment efficacy and patient compliance [1][8][9] - The collaboration aims to leverage the strengths of both drugs, addressing the complex mechanisms involved in MASH treatment [9][10] - The focus on combination therapies is seen as a necessary approach to navigate the competitive landscape and improve patient outcomes [10][12]

Core Insights - Yum China (09987.HK) reported a 14% increase in operating profit to $304 million for Q2 2025, achieving a record high for the second quarter [1] - Total revenue grew by 4% year-on-year to $2.8 billion, with the same growth rate excluding foreign exchange impacts [1] - The operating profit margin reached 10.9%, up 100 basis points year-on-year, driven by improved restaurant profit margins and reduced management expenses [1] Financial Performance - Core operating profit also increased by 14% year-on-year [1] - Diluted earnings per share rose by 5% to $0.58, marking another record high for the second quarter [1] - Excluding the impact of foreign exchange and a $0.04 adjustment for equity investments, diluted earnings per share increased by 15% [1] Sales and Growth Metrics - System sales increased by 4% year-on-year, benefiting from a net addition of 336 stores and a 1% same-store sales growth [2] - Same-store transaction volume grew by 2%, marking the tenth consecutive quarter of growth [2] - Delivery sales surged by 22%, accounting for approximately 45% of restaurant revenue, with digital order revenue reaching $2.4 billion, representing 94% of restaurant income [2] Customer Engagement and Strategy - The combined membership for KFC and Pizza Hut reached approximately 560 million, a 13% increase year-on-year, with member sales accounting for 64% of system sales [2] - The CEO highlighted the company's focus on efficiency and innovation, with successful product launches driving customer engagement [3][4] - KFC expanded its coffee offerings to over 1,300 locations, while Pizza Hut introduced new menu items to attract previously untapped customer segments [4] Shareholder Returns - Yum China returned $274 million to shareholders in Q2, including $184 million in stock buybacks and $90 million in cash dividends [2]

Major Events - Shiyao Group's (01093) application for the listing of Semaglutide injection has been accepted by the National Medical Products Administration (NMPA) [1] - Gilead Sciences-B (01672) has completed the enrollment of overweight or obese subjects in the Phase IIa study of the small molecule oral GLP-1R agonist ASC30 in the United States [1] - China Biopharmaceutical (01177) has received NMPA approval for the clinical trial application of TQC3302 "ICS/LAMA/LABA soft mist inhalation preparation" [1] - Jiaogepeng Holdings (01450) plans to acquire 100% equity of Hangzhou Jiaogepeng Education Technology Co., Ltd. for 180 million yuan [1] Financial Data - China Tower (00788) reported a mid-term profit attributable to shareholders of 5.757 billion yuan, an increase of 8.0% year-on-year, with the revenue share from its two wings business exceeding 14% [1] - Techtronic Industries (00669) reported a mid-term profit attributable to shareholders of 628 million USD, an increase of 14.17% year-on-year, with a dividend of 1.25 HKD per share [1] - Yum China (09987) reported a second-quarter operating profit of 304 million USD, a year-on-year increase of 14% [1] - Zibuyu (02420) issued a profit warning, expecting mid-term revenue to increase by approximately 30%-40% to between 1.9 billion and 2.047 billion yuan [1] - Angelalign (06699) issued a profit warning, expecting net profit for the first half of the year to be approximately 13.4 million to 14.8 million USD, a year-on-year increase of approximately 538.1% to 604.8% [1] - Boya Interactive (00434) issued a profit warning, expecting mid-term profit attributable to shareholders to decrease by approximately 25% to 35% [1] - Zhenjiu Lidu (06979) issued a profit warning, expecting mid-term net profit attributable to shareholders to decline by 23% to 24% [1] - Fourth Paradigm (06682) expects a narrowed adjusted net loss for the mid-term, down 68% to 73% year-on-year [1]

Core Insights - The company announced the completion of participant enrollment for the 13-week Phase IIa study of ASC30, a small molecule oral GLP-1 receptor agonist for obesity treatment, with 125 subjects enrolled [1][2] - The CEO expressed optimism about ASC30's potential as a differentiated therapy for obesity, highlighting the urgent need for more treatment options in the market [1] - The Phase IIa study aims to evaluate the efficacy, safety, and tolerability of ASC30 in obese subjects and overweight subjects with at least one weight-related comorbidity [1] Study Details - The study is randomized, double-blind, placebo-controlled, and multi-center, focusing on two oral formulations of ASC30 [1] - The primary endpoint is the percentage change in average weight from baseline at week 13 [1] - Both formulations will start at a dose of 1 mg, with weekly titrations to reach target maintenance doses of 20 mg and 40 mg for formulation 1, and 20 mg, 40 mg, and 60 mg for formulation 2 [1] Drug Characteristics - ASC30 is the first and only small molecule GLP-1R biased agonist that can be administered both orally and via monthly subcutaneous injection [2] - The drug is a new chemical entity (NCE) with patent protection in the U.S. and globally until 2044, excluding any patent extensions [2] - Formulation 2 has shown a smoother pharmacokinetic profile compared to formulation 1 in previous studies [2]

两种制剂均已在ASC30口服Ia期单剂量递增(SAD)研究(NCT06680440)中进行了评估。制剂2相较制剂1 显示出更平缓的药代动力学特征。 歌礼制药-B(01672)发布公告，评估小分子口服GLP-1受体(GLP-1R)激动剂ASC30治疗肥胖症的美国13周 IIa期研究(NCT07002905)已完成入组。125例受试者均为肥胖人群或伴有至少一种体重相关合并症的超 重人群。 "我们很高兴宣布这一重要里程碑，这标志着ASC30在有望成为治疗肥胖症的独特差异化疗法的道路上 又迈进一步。"歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示，"完成125名受试者入组仅用时 一个多月，凸显了肥胖症市场迫切需要更多治疗选择。我们热切期待在2025年第四季度获得这项IIa期 研究的顶线数据。作为一种小分子药物，如获批，ASC30有望提供每日一次口服和每月一次皮下注射两 种给药选择治疗肥胖症。" 这项IIa期研究是一项13周、随机、双盲、安慰剂对照和多中心的研究，旨在评估ASC30在肥胖受试者 (体重指数(BMI)≥30kg/m2)或伴有至少一种体重相关合并症的超重受试者(27kg/m2≤BMI<30kg/m2)中的 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 歌禮完成小分子口服GLP-1R激動劑ASC30美國IIa期研究 肥胖或超重受試者入組 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣佈，評估小分子口服GLP-1受體(GLP-1R) 激動劑ASC30治療肥胖症的美國13周IIa期研究(NCT07002905)已完成入組。125 例受試者均為肥胖人群或伴有至少一種體重相關合併症的超重人群。 「我們很高興宣佈這一重要里程碑，這標誌着ASC30在有望成為治療肥胖症的獨 特差異化療法的道路上又邁進一步。」歌禮創始人、董事會主席兼首席執行官吳 勁梓博士表示，「完成125名受試者入組僅用時一個多月，凸顯 ...

Market Overview - The Hong Kong stock market showed a rebound with the Hang Seng Index rising by 0.68% to close at 24,902.53 points, with a total trading volume of HKD 2,293.99 million [1] - The Hang Seng China Enterprises Index increased by 0.65%, while the Hang Seng Tech Index rose by 0.73% [1] Blue-Chip Stocks Performance - Lenovo Group (00992) reached a new high in over four months, closing up 5.09% at HKD 11.14, contributing 6.8 points to the Hang Seng Index [2] - BYD Electronics (00285) rose by 7.73%, while Bank of China Hong Kong (02388) increased by 4.69% [2] - New Oriental Education (09901) and China Resources Beer (00291) saw declines of 1.26% and 1.1%, respectively [2] Sector Highlights Pharmaceutical Sector - The pharmaceutical sector saw a resurgence, with Junshi Biosciences (01877) soaring by 33.75% to HKD 32.18 [3] - Other notable gains included Genscript Biotech (01672) up 15.39% and Lepu Medical (02157) up 14.78% [3] - Haitong International expressed optimism for the innovative drug industry, suggesting increased allocation to leading innovative drug and CXO companies [4] Paper Industry - The paper industry is experiencing a price increase, with companies like Nine Dragons Paper (02689) and Lee & Man Paper (02314) seeing significant gains [5] - The industry is benefiting from a supply-demand imbalance and a push for high-quality development [5] Steel Sector - The steel sector was active, with Maanshan Iron & Steel (00323) rising by 15.53% [6] - The government’s focus on capacity management is expected to improve profitability in the long term [6] Gaming and Casino Sector - Macau's gaming stocks surged, with major players like MGM China (02282) and Wynn Macau (01128) seeing increases following a strong July revenue report [6] - Macau's gaming revenue reached MOP 221.25 billion, a 19% year-on-year increase, indicating a recovery in demand [6] Notable Stock Movements - Xindong Company (02400) surged by 24.76% after announcing a positive earnings forecast for the first half of 2025 [7] - Oriental Selection (01797) rose by 16.82% following a quarterly earnings report showing improved profitability [8] - China Tower (00788) reported stable revenue growth of RMB 49.601 billion, up 2.8% year-on-year, with a profit increase of 8.0% [10]

Group 1 - The Hong Kong biotechnology stocks collectively rose, with notable increases in several companies' stock prices [1][2] - Beihai Kangcheng-B saw a rise of nearly 19%, while other companies like Gilead Sciences-B and Ascentage Pharma-B also experienced significant gains of over 15% and 9% respectively [1][2] - The overall trend indicates a positive sentiment in the biotechnology sector, with multiple companies achieving gains of over 5% [1][2] Group 2 - Specific stock performance includes: Beihai Kangcheng-B at 18.99% increase, Gilead Sciences-B at 15.30%, and Ascentage Pharma-B at 9.48% [2] - The market capitalization of these companies varies significantly, with Gilead Sciences-B at approximately 11.477 billion and Ascentage Pharma-B at about 29.86 billion [2] - Other notable performers include Jiahua Bio-B and Beikang Medical-B, both showing increases of over 7% [1][2]

Group 1 - The Hong Kong biotechnology sector experienced a rise on August 5, with notable increases in stock prices for several companies [1] - Gilead Sciences (歌礼制药) saw a surge of over 15% in its stock price [1] - Ascentage Pharma (亚盛医药) increased by more than 9% [1] - Other companies such as Jiahe Biopharma (嘉和生物) and Innovent Biologics (复宏汉霖) rose by over 8% [1] - CanSino Biologics (康希诺生物) and Zai Lab (再鼎医药) experienced increases of over 5% [1]